Abstracts tagged "Patient reported outcomes"

Abstract Number: 0142 • ACR Convergence 2020
Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs: Results from the FINCH 2 Study
Zobair Younossi¹, Maria Stepanova², Lynn Gerber¹, Susan Lee³, I-Heng Lee⁴, Thijs Hendrikx⁵, Annelies Boonen⁶, Rieke Alten⁷, Bernard Combe⁸ and David Walker⁹, ¹Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, ²Center for Outcomes Research in Liver Disease, Washington, DC, ³Gilead Sciences, Inc., Foster City, CA, ⁴Gilead Sciences, Foster City, CA, ⁵Galapagos BV, Leiden, Netherlands, ⁶Maastricht University Medical Center, Maastricht, Netherlands, ⁷Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany, ⁸University of Montpellier, Montpellier, France, ⁹Northumbria Healthcare Trust, North Shields, United Kingdom
Background/Purpose: Filgotinib (FIL) is a potent oral selective janus kinase 1 inhibitor which is currently being investigated as an agent to treat rheumatoid arthritis (RA).…
Abstract Number: 0169 • ACR Convergence 2020
Patient-Reported Outcomes Differentiate Between Remission and Low Disease Activity in Psoriatic Arthritis
Juliette Yedimenko¹, Jessica Walsh², Alexis Ogdie³, Yuxuan Jin¹, Soumya Reddy⁴, Jose Scher⁵ and M. Elaine Husni¹, ¹Cleveland Clinic, Cleveland, OH, ²University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ³Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴NYU School of Medicine, New York, NY, ⁵NYU School of Medicine, New York City
Background/Purpose: For psoriatic arthritis (PsA), several different composite instruments are available to define low disease activity (LDA) and remission (REM) targets for treatment. Patient-reported outcomes…
Abstract Number: 0354 • ACR Convergence 2020
How Do TNF-alpha-Inhibitors in Medical History Affect Patient Reported Outcomes and Retention in Ankylosing Spondylitis Patients Treated with Secukinumab in Real World? – German Observational Study
Uta Kiltz¹, Jan Brandt-Jürgens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ²Rheumatologische Schwerpunktpraxis Berlin, Berlin, Germany, ³Ambulantes Rheumazentrum, Erfurt, Germany, ⁴Hannover Medical School, Hannover, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany
Background/Purpose: Secukinumab (SEC), a fully human monoclonal antibody that selectively inhibits interleukin 17A, is approved for treatment of patients with ankylosing spondylitis (AS). However, there…
Abstract Number: 0831 • ACR Convergence 2020
Sociodemographic, Disease, and Medication Profile of RA Patients Under 65 Years Compared with 65 Years or Older at Registry Enrollment: Real World Results from a Rheumatoid Arthritis Cohort
Mohammad Movahedi¹, Angela Cesta², Xiuying Li³ and Claire Bombardier⁴, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, Toronto, Canada, ⁴Institute for Work and Health, Toronto, ON, Canada
Background/Purpose: Age is an important factor that can affect disease course, physical function and treat to target strategy for patients with rheumatoid arthritis (RA). We…
Abstract Number: 1145 • ACR Convergence 2020
Implementation of Web-Based Patient-Reported Outcome Measures (PROMs) in SLE Clinical Care: A Multi-Center Prospective Cohort Study
Shanthini Kasturi¹, Lori Lyn Price¹, David Curtis², William Nowell³, Norma Terrin¹, Jane Salmon⁴, Lisa Mandl⁴ and Timothy McAlindon¹, ¹Tufts Medical Center, Boston, MA, ²Global Healthy Living Foundation, New York City, ³Global Healthy Living Foundation, New York City, NY, ⁴Hospital for Special Surgery, New York, NY
Background/Purpose: Patient-reported outcome measures (PROMs) are powerful tools which can highlight the patient experience of illness. Although PROMs are standard metrics in SLE clinical research,…
Abstract Number: 1289 • ACR Convergence 2020
Sex Differences in Mental Health and Quality of Life and Their Impact in the Treatment of Patients with Systemic Lupus Erythematosus
Lilian Cano-Cruz¹, Eduardo Aguirre-Aguilar¹, Martín Valdez-López², Ana Barrera-Vargas¹, Virginia Pascual Ramos¹ and Javier Merayo-Chalico³, ¹INSTITUTO NACIONAL DE CIENCIAS MEDICAS Y NUTRICION SALVADOR ZUBIRAN, Mexico City, Distrito Federal, Mexico, ²INSTITUTO NACIONAL DE CIENCIAS MEDICAS Y NUTRICION SALVADOR ZUBIRAN, Mexico City, Mexico, ³INSTITUTO NACIONAL DE CIENCIAS MEDICAS Y NUTRICION SALVADOR ZUBIRAN, Ciudad de Mexico, Distrito Federal, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) predominantly affects young women. It is usually more aggressive in men and carries a worse prognosis. Information about gender differences…
Abstract Number: 1596 • ACR Convergence 2020
Coproduction of Care for Veterans with RA: Improving Elicitation and Documentation of Patient Goals
Swathi Reddy¹, Kyawt Shwin¹, Rashmi Arora¹, Sarah Homann², Lisa Johnson³, Yusuf Chao⁴, Aricca Van Citters³, Brant Oliver⁵, Guy Eakin⁶, Eugene Nelson³, Andreas Reimold¹ and Salahuddin Kazi¹, ¹Veterans Affairs North Texas Healthcare System / UT Southwestern Medical Center, Dallas, TX, ²Veterans Affairs Tennessee Valley Healthcare System / Vanderbilt University Medical Center, Nashville, TN, ³The Dartmouth Institute for Health Policy & Clinical Practice, Lebanon, NH, ⁴UT Southwestern Medical Center, Dallas, TX, ⁵The Dartmouth Institute for Health Policy & Clinical Practice / Veterans Affairs National Quality Scholars Fellowship in Healthcare Quality & Safety, Lebanon, NH, ⁶Arthritis Foundation, Atlanta, GA
Background/Purpose: Coproduction of healthcare services offers a pathway to increase patient engagement in care. Patients and clinicians coproduce care by working together to: (1) co-assess…
Abstract Number: 1842 • ACR Convergence 2020
Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus: Post Hoc Analyses of Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-blind, Placebo-Controlled Trial
Anca Askanase¹, George Wan², Mary Panaccio², Enxu Zhao², Julie Zhu², Roman Bilyk² and Richard Furie³, ¹Columbia University College of Physicians and Surgeons, New York, NY, ²Mallinckrodt Pharmaceuticals, Bedminster, NJ, ³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY
Background/Purpose: Repository corticotropin injection (RCI, Mallinckrodt Pharmaceuticals) is a naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides approved for the treatment…
Abstract Number: 0143 • ACR Convergence 2020
Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis Who Are Methotrexate-naïve: Results from the FINCH-3 Study
Zobair Younossi¹, Maria Stepanova², Lynn Gerber¹, Susan Lee³, Ken Hasegawa³, Thijs Hendrikx⁴, Annelies Boonen⁵, Bernard Combe⁶, David Walker⁷ and Rieke Alten⁸, ¹Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, ²Center for Outcomes Research in Liver Disease, Washington, DC, ³Gilead Sciences, Inc., Foster City, CA, ⁴Galapagos BV, Leiden, Netherlands, ⁵Maastricht University Medical Center, Maastricht, Netherlands, ⁶University of Montpellier, Montpellier, France, ⁷Northumbria Healthcare Trust, North Shields, United Kingdom, ⁸Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany
Background/Purpose: Filgotinib (FIL) is a potent oral selective janus kinase 1 inhibitor currently being investigated as an agent to treat rheumatoid arthritis (RA). In the…
Abstract Number: 0186 • ACR Convergence 2020
The Number of Associated Comorbidities Can Impact Disease Activity Scores Independently from Objective Measures of Inflammation in Patients with Rheumatoid Arthritis
Magali Zanotti-Cavazzoni¹ and Gabriela Avila², ¹Sociedad Paraguaya de Reumatología, Asunción, Paraguay, ²Sociedad Paraguaya de Reumatologia, Asuncion, Paraguay
Background/Purpose: Disease activity scores (DAS) are used as tools to assess persistent inflammation and need for therapeutic escalation in patients with Rheumatoid arthritis (RA). One…
Abstract Number: 0356 • ACR Convergence 2020
Bimekizumab Improves Patient-Reported Outcomes in Psoriatic Arthritis: 48-Week Results from a Phase 2b Study and Association Between Patient-Reported Outcomes and Disease Activity
Laure Gossec¹, Philip Mease², Alice Gottlieb³, Deepak Assudani⁴, Jason Coarse⁵, Barbara Ink⁶ and Laura Coates⁷, ¹Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Raleigh, NC, ⁶UCB Pharma, Slough, ⁷University of Oxford, Oxford, United Kingdom
Background/Purpose: Bimekizumab (BKZ), a humanized monoclonal IgG1 antibody that selectively neutralizes interleukin (IL)-17A and IL-17F, has shown clinical improvements in joint and skin outcomes and…
Abstract Number: 0863 • ACR Convergence 2020
Residual Treatment Burden, Desired Improvement, and Prioritized Treatment Goals in Systemic Lupus Erythematosus (SLE): Results from the SLE-UPDATE (Understanding Preferences, Disease Activity and Treatment Expectations) Survey in the United States
Diane Kamen¹, Julie Birt², Monica Hadi³, Nashmel Sargalo³, Ella Brookes³, Paul Swinburn³, Leslie Hanrahan⁴, Karin Tse⁵, Natalia Bello⁶, Kirstin Griffing², Maria Silk², Laure Delbecque⁷ and Anca Askanase⁸, ¹Medical University of South Carolina, Charleston, SC, ²Eli Lilly and Company, Indianapolis, IN, ³Evidera, London, United Kingdom, ⁴Carra Group, Milwaukee, WI, ⁵Lupus Foundation of America, DC, WA, ⁶Eli Lilly and Company, Indianapolis, ⁷Eli Lilly and Company, Brussels, Belgium, ⁸Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Literature describes a fairly high degree of satisfaction with SLE therapies, despite patients reporting high rates of adverse event (1-2). The objectives of this…
Abstract Number: 1177 • ACR Convergence 2020
Rheumatic Diseases in Mexican Children and Their Psychosocial and Economic Impact on Caregivers
Fernando García Rodríguez¹, Brenda de Jesús Fortuna², Ingris Pelaez-Ballestas³, Enrique Faugier Fuentes⁴, Samara Mendieta Zerón⁵, Greta Reyes Cordero⁶, Sol Jiménez Hernández⁷, Ana Villarreal Treviño⁸, Jessica Guadarrama⁹, Sara Rosiles de la Garza⁸, Manuel de la O Cavazos⁸ and Nadina Rubio Pérez¹⁰, ¹Hospital Universitario "Dr. José E. González", Mexico City, Nuevo Leon, Mexico, ²Hospital Infantil De México Federico Gómez, Monterrey, Nuevo Leon, Mexico, ³Hospital General de Mexico, Mexico, Distrito Federal, Mexico, ⁴Hospital Infantil de México Federico Gómez, CDMX, Distrito Federal, Mexico, ⁵ISSEMYM Toluca, Estado de México, Distrito Federal, Mexico, ⁶Hospital Infantil de Especialidades de Chihuahua, Chihuahua, Chihuahua, Mexico, ⁷Hospital Universitario "Dr. José E. González", Monterrey, Mexico, ⁸Hospital Universitario "Dr.José E. González", Monterrey, Nuevo Leon, Mexico, ⁹Hospital Infantil de México Federico Gómez, CDMX, Distrito Federal, Mexico, ¹⁰Hospital Universitario "Dr. José E. González", Monterrey, Nuevo Leon, Mexico
Background/Purpose: Pediatric rheumatic diseases (PRD) are a heterogeneous group of disorders. PRD patients and their caregivers face a number of challenges, these include the consequences…
Abstract Number: 1290 • ACR Convergence 2020
A Multitrait-Multimethod Matrix Approach to the Construct Validity of Patient Reported Outcomes Measurement Information System Computerized (PROMIS) Adaptive Tests (CAT) in Systemic Lupus Erythematous
Mitra Moazzami¹, Patricia Katz², Dennisse Bonilla³, Lisa Engel⁴, Jiandong Su⁵, Pooneh Akhavan⁶, Nicole Anderson⁵, Oshrat Tayer-Shifman⁷, Dorcas Beaton⁸ and Zahi Touma⁹, ¹George Washington University School of Medicine, Washington, DC, ²University of California, San Francisco, Novato, CA, ³University Health Network, Toronto, Canada, ⁴University of Manitoba, Toronto, ON, Canada, ⁵University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁶Univesity of Toronto, Toronto, ON, Canada, ⁷Meir Medical Center, Raanana, Israel, ⁸Institue for Work and Health, Toronto, ON, Canada, ⁹University of Toronto, Toronto, ON, Canada
Background/Purpose: Use of The Patient Reported Outcomes Measurement Information System computerized adaptive test (PROMIS-CAT) in adults with systemic lupus erythematous (SLE) is an emerging research…
Abstract Number: 1599 • ACR Convergence 2020
Workflows for Collecting and Using Patient-reported Outcomes Across Rheumatology Practices
Meera Subash¹, Kimberly DeQuattro², Sonam Choden³, Lucy Liu⁴, Puneet Bajaj⁵, Christie Bartels⁶, Jennifer Barton⁷, Bonnie Bermas⁸, Maria (Maio) Danila⁹, Julianna Desmarais¹⁰, Christina Downey¹¹, Sancia Ferguson¹², Sarah Goglin¹³, Margaret Guthrie¹⁴, Irum Jan¹⁵, Nikila Kumar¹⁶, Shraddha Prakash¹⁷, Kimberly Reiter¹⁸, Elizabeth Wahl¹⁹, Elena Weinstein²⁰, JoAnn Zell²¹, Gabriela Schmajuk²² and Jinoos Yazdany², ¹University of California, San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA, ³University of California, San Francisco, San Francisco, ⁴Kaiser Permanente, Oakland, CA, ⁵UT Southwestern, Dallas, TX, ⁶University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI, ⁷VAPORHCS/OHSU, Portland, OR, ⁸UTSouthwestern.edu, Dallas, TX, ⁹University of Alabama at Birmingham (UAB), Birmingham, AL, ¹⁰Oregon Health & Science University, Portland, OR, ¹¹Loma Linda University Medical Center, Redlands, CA, ¹²University of Wisconsin-Madison School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Oakland, CA, ¹³University of California San Francisco, Burlingame, CA, ¹⁴University of Alabama at Birmingham, DIv. of Clinical immunology & Rheum., Birmingham, AL, ¹⁵VA Albuquerque, Albuquerque, ¹⁶Arizona Arthritis & Rheumatology Associates, P.C., San Jose, CA, ¹⁷Oakcare Medical Group, Pleasanton, CA, ¹⁸Albuquerque VA Medical Center, Albuquerque, NM, ¹⁹VA Puget Sound Healthcare System, Seattle, WA, ²⁰University of Colorado, Englewood, CO, ²¹University of Colorado, Denver, CO, ²²University of California, San Francisco, Atherton, CA
Background/Purpose: The use of patient reported outcomes (PROs) during rheumatology visits may facilitate shared decision making and encourage patients to share their health goals. However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.